---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-26-000574"
form_type: "8-K"
ticker: "ARTL"
cik: "0001621221"
company_name: "ARTELO BIOSCIENCES, INC."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:23:35.453226+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Artelo Biosciences closes $11M private placement; expects to regain Nasdaq compliance

## Summary
- Gross proceeds $11.0M from sale of 3.19M common shares (or pre-funded warrants) and 6.38M common warrants at $3.45/unit.
- Net proceeds of $10.03M to be used for working capital, corporate purposes, and repayment of bridge debt.
- Common warrants exercisable at $3.20 for 5.5 years; potential additional proceeds of $20.4M if fully cash-exercised.
- Proceeds push stockholders' equity above $2.5M threshold; company awaiting Nasdaq confirmation of compliance.
- H.C. Wainwright acted as placement agent, receiving 8% cash fee plus warrants for 255,073 shares at $4.3125.

## SEC filing metadata
- accession: 0001640334-26-000574
- form_type: 8-K
- ticker: ARTL
- cik: 0001621221
- company_name: ARTELO BIOSCIENCES, INC.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000574/0001640334-26-000574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000574/artl_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-26-000574
- JSON: https://secwatch.observer/filing/0001640334-26-000574.json
- Plain text: https://secwatch.observer/filing/0001640334-26-000574.txt

## Key facts
- Material Agreements
  ARTELO BIOSCIENCES, INC. entered into Purchase Agreement with certain accredited investors valued at $10,996,902.70 (effective 2026-03-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $10,996,902.70
  - Effective: 2026-03-27
  source text: On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000574/0001640334-26-000574-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.